Researchers in the Journal of Translational Medicine say the 16 amino acid peptide protects metabolism in some settings but may aid tumors in others, and human data is inconsistent.
Recap by typeshit. Full story at BIOENGINEER.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
Holly Lofton says some patients using gray-market reta saw no weight loss at all, since those products often lack the active ingredient. UK approval is still pending.
PBS News reports roughly one in eight Americans are on GLP-1 weight loss drugs and looks at what comes with their popularity.
Loading…